Literature DB >> 22962270

T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion.

James P Hindley1, Emma Jones, Kathryn Smart, Hayley Bridgeman, Sarah N Lauder, Beatrice Ondondo, Scott Cutting, Kristin Ladell, Katherine K Wynn, David Withers, David A Price, Ann Ager, Andrew J Godkin, Awen M Gallimore.   

Abstract

The evolution of immune blockades in tumors limits successful antitumor immunity, but the mechanisms underlying this process are not fully understood. Depletion of regulatory T cells (Treg), a T-cell subset that dampens excessive inflammatory and autoreactive responses, can allow activation of tumor-specific T cells. However, cancer immunotherapy studies have shown that a persistent failure of activated lymphocytes to infiltrate tumors remains a fundamental problem. In evaluating this issue, we found that despite an increase in T-cell activation and proliferation following Treg depletion, there was no significant association with tumor growth rate. In contrast, there was a highly significant association between low tumor growth rate and the extent of T-cell infiltration. Further analyses revealed a total concordance between low tumor growth rate, high T-cell infiltration, and the presence of high endothelial venules (HEV). HEV are blood vessels normally found in secondary lymphoid tissue where they are specialized for lymphocyte recruitment. Thus, our findings suggest that Treg depletion may promote HEV neogenesis, facilitating increased lymphocyte infiltration and destruction of the tumor tissue. These findings are important as they point to a hitherto unidentified role of Tregs, the manipulation of which may refine strategies for more effective cancer immunotherapy. ©2012 AACR.

Entities:  

Mesh:

Year:  2012        PMID: 22962270      PMCID: PMC3491872          DOI: 10.1158/0008-5472.CAN-12-1912

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.

Authors:  D Schrama; P thor Straten; W H Fischer; A D McLellan; E B Bröcker; R A Reisfeld; J C Becker
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

2.  Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

Authors:  Michele W L Teng; Shin Foong Ngiow; Bianca von Scheidt; Nicole McLaughlin; Tim Sparwasser; Mark J Smyth
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

3.  Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.

Authors:  Katjana Klages; Christian T Mayer; Katharina Lahl; Christoph Loddenkemper; Michele W L Teng; Shin Foong Ngiow; Mark J Smyth; Alf Hamann; Jochen Huehn; Tim Sparwasser
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

4.  Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules.

Authors:  Christine Moussion; Jean-Philippe Girard
Journal:  Nature       Date:  2011-11-13       Impact factor: 49.962

Review 5.  Fate and function of lymphoid tissue inducer cells.

Authors:  Daniela Finke
Journal:  Curr Opin Immunol       Date:  2005-04       Impact factor: 7.486

6.  Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response.

Authors:  Olivier Thaunat; Anne-Christine Field; Jianping Dai; Liliane Louedec; Natacha Patey; Marie-Françoise Bloch; Chantal Mandet; Marie-France Belair; Patrick Bruneval; Olivier Meilhac; Blanche Bellon; Etienne Joly; Jean-Baptiste Michel; Antonino Nicoletti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-28       Impact factor: 11.205

7.  Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses.

Authors:  M A Houtkamp; O J de Boer; C M van der Loos; A C van der Wal; A E Becker
Journal:  J Pathol       Date:  2001-02       Impact factor: 7.996

8.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.

Authors:  Jeong M Kim; Jeffrey P Rasmussen; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2006-11-30       Impact factor: 25.606

9.  A HEV-restricted sulfotransferase is expressed in rheumatoid arthritis synovium and is induced by lymphotoxin-alpha/beta and TNF-alpha in cultured endothelial cells.

Authors:  José L Pablos; Begoña Santiago; Durwin Tsay; Mark S Singer; Guillermo Palao; María Galindo; Steven D Rosen
Journal:  BMC Immunol       Date:  2005-03-07       Impact factor: 3.615

10.  The impact of regulatory T cells on carcinogen-induced sarcogenesis.

Authors:  G Betts; J Twohig; M Van den Broek; S Sierro; A Godkin; A Gallimore
Journal:  Br J Cancer       Date:  2007-06-12       Impact factor: 7.640

View more
  51 in total

Review 1.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience.

Authors:  Milena Gulinac; Dorian Dikov; Simeon Lichev; Tsvetelina Velikova
Journal:  Am J Clin Exp Immunol       Date:  2020-12-15

3.  Immunotherapy: HEV: the gateway to tumour control?

Authors:  Mina Razzak
Journal:  Nat Rev Clin Oncol       Date:  2012-09-25       Impact factor: 66.675

Review 4.  Inflammation-induced lymphangiogenesis and lymphatic dysfunction.

Authors:  Shan Liao; Pierre-Yves von der Weid
Journal:  Angiogenesis       Date:  2014-01-22       Impact factor: 9.596

5.  Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.

Authors:  Jing Cui; Qi Zhang; Qi Song; Herui Wang; Pauline Dmitriev; Mitchell Y Sun; Xiaoyu Cao; Yang Wang; Liemei Guo; Iris H Indig; Jared S Rosenblum; Chunxia Ji; Dongqing Cao; Kaiyong Yang; Mark R Gilbert; Yu Yao; Zhengping Zhuang
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

Review 6.  Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.

Authors:  J David Peske; Amber B Woods; Victor H Engelhard
Journal:  Adv Cancer Res       Date:  2015-06-01       Impact factor: 6.242

7.  Differential control of immune cell homeostasis by Foxp3(+) regulatory T cells in murine peripheral lymph nodes and spleen.

Authors:  Pedro Milanez-Almeida; Frank Klawonn; Michael Meyer-Hermann; Jochen Huehn
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-09-11

Review 8.  Tertiary lymphoid structures in the era of cancer immunotherapy.

Authors:  Catherine Sautès-Fridman; Florent Petitprez; Julien Calderaro; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

Review 9.  Immune crosstalk in cancer progression and metastatic spread: a complex conversation.

Authors:  Hannah Garner; Karin E de Visser
Journal:  Nat Rev Immunol       Date:  2020-02-05       Impact factor: 53.106

10.  Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction.

Authors:  Emily J Colbeck; Emma Jones; James P Hindley; Kathryn Smart; Ralph Schulz; Molly Browne; Scott Cutting; Anwen Williams; Lee Parry; Andrew Godkin; Carl F Ware; Ann Ager; Awen Gallimore
Journal:  Cancer Immunol Res       Date:  2017-09-25       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.